392 related articles for article (PubMed ID: 7845006)
1. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.
Smetsers TF; van de Locht LT; Pennings AH; Wessels HM; de Witte TM; Mensink EJ
Leukemia; 1995 Jan; 9(1):118-30. PubMed ID: 7845006
[TBL] [Abstract][Full Text] [Related]
2. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
Smetsers TF; Skorski T; van de Locht LT; Wessels HM; Pennings AH; de Witte T; Calabretta B; Mensink EJ
Leukemia; 1994 Jan; 8(1):129-40. PubMed ID: 8289478
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
[TBL] [Abstract][Full Text] [Related]
4. Phosphorothioate-capped antisense oligonucleotides to Ras GAP inhibit cell proliferation and trigger apoptosis but fail to downregulate GAP gene expression.
White JR; Gordon-Smith EC; Rutherford TR
Biochem Biophys Res Commun; 1996 Oct; 227(1):118-24. PubMed ID: 8858112
[TBL] [Abstract][Full Text] [Related]
5. Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines.
O'Brien SG; Kirkland MA; Melo JV; Rao MH; Davidson RJ; McDonald C; Goldman JM
Leukemia; 1994 Dec; 8(12):2156-62. PubMed ID: 7808004
[TBL] [Abstract][Full Text] [Related]
6. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
7. Sequence specificity on the growth suppression and induction of apoptosis of chronic myeloid leukemia cells by BCR-ABL anti-sense oligodeoxynucleoside phosphorothioates.
Maekawa T; Kimura S; Hirakawa K; Murakami A; Zon G; Abe T
Int J Cancer; 1995 Jul; 62(1):63-9. PubMed ID: 7601569
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
[TBL] [Abstract][Full Text] [Related]
9. The effect of bcr-abl antisense oligonucleotide on DNA synthesis and apoptosis in K562 chronic myeloid leukemia cells.
Rowley PT; Keng PC; Kosciolek BA
Leuk Res; 1996 Jun; 20(6):473-80. PubMed ID: 8709619
[TBL] [Abstract][Full Text] [Related]
10. Morpholino Oligo Antisense efficiently suppresses BCR/ABL and cell proliferation in CML: specific inhibition of BCR-ABL gene expression by Morpholino Oligo Antisense in BCR-ABL(+) cells.
Haririan M; Kaviani S; Soleimani M; Ghaemi SR; Delalat B; Atashi A
Hematology; 2012 Jan; 17(1):28-34. PubMed ID: 22549445
[TBL] [Abstract][Full Text] [Related]
11. An antisense Bcr-Abl phosphodiester-tailed methylphosphonate oligonucleotide reduces the growth of chronic myeloid leukaemia patient cells by a non-antisense mechanism.
Smetsers TF; Linders EH; van de Locht LT; de Witte TM; Mensink EJ
Br J Haematol; 1997 Feb; 96(2):377-81. PubMed ID: 9029029
[TBL] [Abstract][Full Text] [Related]
12. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
Wetzler M; Talpaz M; Van Etten RA; Hirsh-Ginsberg C; Beran M; Kurzrock R
J Clin Invest; 1993 Oct; 92(4):1925-39. PubMed ID: 8408645
[TBL] [Abstract][Full Text] [Related]
13. Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.
Vaerman JL; Lewalle P; Martiat P
Stem Cells; 1993 Oct; 11 Suppl 3():89-95. PubMed ID: 8298481
[TBL] [Abstract][Full Text] [Related]
14. Circular antisense oligonucleotides inhibit growth of chronic myeloid leukemia cells.
Rowley PT; Kosciolek BA; Kool ET
Mol Med; 1999 Oct; 5(10):693-700. PubMed ID: 10602778
[TBL] [Abstract][Full Text] [Related]
15. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
Skórski T; Szczylik C; Malaguarnera L; Calabretta B
Folia Histochem Cytobiol; 1991; 29(3):85-9. PubMed ID: 1794439
[TBL] [Abstract][Full Text] [Related]
16. The repression of apoptosis by activated abl oncogenes in chronic myelogenous leukaemia.
Fernandes RS; Gorman AM; McGahon A; Lawlor M; McCann S; Cotter TG
Leukemia; 1996 Jun; 10 Suppl 2():s17-21. PubMed ID: 8649049
[TBL] [Abstract][Full Text] [Related]
17. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
18. Capping of bcr-abl antisense oligonucleotides enhances antiproliferative activity against chronic myeloid leukemia cell lines.
Thomas M; Kosciolek B; Wang N; Rowley P
Leuk Res; 1994 Jun; 18(6):401-8. PubMed ID: 8207957
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
20. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines.
Algar EM; Khromykh T; Smith SI; Blackburn DM; Bryson GJ; Smith PJ
Oncogene; 1996 Mar; 12(5):1005-14. PubMed ID: 8649791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
